Richard Thomas Williams - Sep 1, 2022 Form 4 Insider Report for Kinnate Biopharma Inc. (KNTE)

Role
Chief Medical Officer
Signature
/s/ Mark A. Meltz, as attorney-in-fact
Stock symbol
KNTE
Transactions as of
Sep 1, 2022
Transactions value $
$0
Form type
4
Date filed
9/2/2022, 05:00 PM
Previous filing
Mar 15, 2022
Next filing
Dec 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNTE Common Stock Award $0 +25K +57.51% $0.00 68.5K Sep 1, 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Issuer granted RSUs to the Reporting Person. Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer. A portion of the RSUs vest each quarter, subject to the Reporting Person's continued service as of each vesting date.
F2 Includes 1,141 shares acquired under the Issuer's Employee Stock Purchase Plan in May 2022.